Loading...

Monensin Solution (1,000X)

Pricing & Availability
Regulatory Status
RUO
Ave. Rating
Submit a Review
Product Citations
publications
Cat # Size Price Quantity Check Availability Save
420701 1 mL 44€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Monensin is a protein transport inhibitor commonly used to enhance intracellular cytokine staining signals by blocking transport processes during cell activation. Especially useful for the intracellular staining of cytokines, monensin leads to the accumulation of most cytokines at the Golgi Complex/Endoplasmic Reticulum (see Jung, et al., 1993). Optimal conditions for use are cell type and time-dependent. Typically, protein transport inhibitors are included during in vitro cell activation cultures for 4-24 hours prior to harvest (see references below for additional information). Monensin Solution is supplied as a 1,000X solution, which should be diluted to 1X in cell culture medium.

Product Details
Technical Data Sheet (pdf)

Product Details

Formulation
Monensin Solution is supplied as a 1000X working solution in 70% Ethanol. Dilute to 1X in cell culture medium.
Concentration
2.0 mM
Storage & Handling
Store the solution between 2°C and 8°C. Monensin is known to be toxic; avoid direct body contact. Ethanol is flammable; keep away from sources of fire.
Application

ICFC - Quality tested
Recommended Usage

Dilute the 1000X solution to 1X in the tissue culture medium. It is recommended that cells are cultured with monensin for ≤ 24 hours, as this can become toxic for cell viability.

Application References
  1. Smeltz RB. 2007. J. Immunol. 178:4786.
  2. Fuse S, et al. 2007. J. Immunol. 178:5227.
  3. Durkin ET,et al. 2008. Blood 10:1182.PubMed
  4. Durkin ET, et al. 2008. Blood 112:5245. PubMed
  5. Liu XS, et al. 2009. J. Immunol. 183:51. PubMed
  6. Mattarollo SR, et al. 2010. J. Immunol. 184:1242. PubMed
  7. Yang M, et al. 2010. J. Immuonl. 184:3321. PubMed
  8. Mattarollo SR, et al. 2010. J. Immunol. 184:5663. PubMed
  9. Wood MW, et al. 2011. Infect Immun. 79:708. PubMed
  10. Janune D, et al. 2011. FEBS Lett. 585:3033. PubMed
  11. Fiorenza S, et al. 2012. J. Immunol. 189:5622. PubMed
  12. Asgari E, et al. 2013. Blood. 122:3473. PubMed
  13. Li D, et al. 2013. Clin Immunol. 149:411. PubMed
  14. Bunse CE, et al. 2013. PLoS One. 8:77925. PubMed
Product Citations
  1. Li D, et al. 2013. Clin Immunol. 149:411. PubMed
  2. Mattarollo S, et al. 2010. J Immunol. 184:1242. PubMed
  3. Pal R, et al. 2020. Curr Protoc Cytom. 92:e69. PubMed
  4. Bhatt RS, et al. 2021. Cancer Immunol Res. 9:156. PubMed
  5. Yu L, et al. 2022. FEBS J. 289:3241. PubMed
  6. Zhang X, et al. 2022. Nat Commun. 13:7582. PubMed
  7. Giannou AD, et al. 2023. Immunity. 56:125. PubMed
  8. Martinelli M, et al. 2023. iScience. 26:105860. PubMed
  9. Zhou H, et al. 2023. Front Immunol. 13:1059687. PubMed
  10. Mandour MF, et al. 2023. Front Med (Lausanne). 9:1057252. PubMed
  11. Pymm P, et al. 2022. Cell Rep. 38:110449. PubMed
  12. Giles JR, et al. 2022. Immunity. 55:557. PubMed
  13. Ye L, et al. 2022. Cell Metab. 34:595. PubMed
  14. Du J, et al. 2022. Sci Immunol. 7:eabo5407. PubMed
  15. Duan LJ, et al. 2022. Cell Rep. 40:111284. PubMed
  16. Lu C, et al. 2023. Antiviral Res. 212:105556. PubMed
  17. Kozlovski S, et al. 2023. Front Immunol. 13:1041552. PubMed
  18. Zhou Y, et al. 2023. Front Immunol. 14:1129705. PubMed
  19. Changsheng H, et al. 2023. Sci Adv. 9:eade4186. PubMed
  20. Comeau K, et al. 2023. Bio Protoc. 13:e4679. PubMed
  21. Frankish J, et al. 2023. Front Immunol. 14:1160116. PubMed
  22. Patskovsky Y, et al. 2023. Nat Commun. 14:3763. PubMed
  23. Qian Y, et al. 2021. Cell Reports. 36(8):109602. PubMed
  24. Andrew Mansour, Laurentiu Pop, Ellen Vitetta 2016. PLoS One. 11:e0167618. PubMed
  25. Asgari E, et al. 2013. Blood. 122:3473. PubMed
  26. Munk R, et al. 2011. PLoS One. 6:e18553. PubMed
  27. Pan YG, et al. 2022. Methods Mol Biol. 2574:31. PubMed
  28. Aguilar-Pineda JA, et al. 2021. iScience. 24:102993. PubMed
  29. Bailey S, et al. 2017. Nat Commun.. 10.1038/s41467-017-01867-9. PubMed
  30. Durkin E, et al. 2008. Blood. 112:5245. PubMed
  31. Yang M, et al. 2010. J Immunol. 184:3321. PubMed
  32. Cook CP, et al. 2022. Cell Rep Med. 3:100715. PubMed
  33. Tian M, et al. 2022. J Clin Invest. 132:. PubMed
  34. Kimura I, et al. 2022. Cell Rep. 38:110218. PubMed
  35. Gao F, et al. 2021. Front Cell Infect Microbiol. 10:593805. PubMed
  36. Izumi K, et al. 2021. Immunohorizons. 5:687. PubMed
  37. Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed
  38. Martens A, et al. 2020. Nat Immunol. 21:381. PubMed
  39. Theeb W, et al. 2017. Infect Immun . 10.1128/IAI.00475-16. PubMed
  40. Al-Attar A, et al. 2016. Data Brief. 8: 536-44. PubMed
  41. Joosten S, et al. 2016. PLoS Pathog. 12: 1005687. PubMed
  42. Fiorenza S, et al. 2012. J Immunol. 189:5622. PubMed
  43. Rana A, et al. 2020. Front Immunol. 11:536. PubMed
  44. Datta A, et al. 2022. J Fungi (Basel). 8:. PubMed
  45. Douthwaite J, et al. 2017. J Immunol. 198(1):528-537. PubMed
  46. Meyer C, Key P 2017. Imm Inflam Dis. 10.1002/iid3.156. PubMed
  47. Montes de Oca M, et al. 2020. PLoS Pathog. 16:e1008994. PubMed
  48. Geisness AC, et al. 2021. Haematologica. Online ahead of print. PubMed
  49. Janune D, et al. 2011. FEBS Lett. 585:3033. PubMed
  50. Park HB, et al. 2020. Oncoimmunology. 9:1772663. PubMed
  51. Ries M, et al. 2017. PLoS Pathog. 10.1371/journal.ppat.1006506. PubMed
  52. Steinbuck MP, et al. 2021. Sci Adv. 7: . PubMed
  53. Acharya A, et al. 2020. J Virol. 95:e01657. PubMed
  54. Takushi SE, et al. 2020. Hum Gene Ther. 31:626. PubMed
  55. Shenoy AT, et al. 2021. Nat Commun. 12:5834. PubMed
  56. Imani J, et al. 2021. JCI Insight. 6:. PubMed
  57. Elliott PR, et al. 2021. Cell Rep. 37:109777. PubMed
  58. Bunting MD, et al. 2022. Sci Adv. 8:eabk3327. PubMed
  59. Uddin MN, et al. 2022. Brain Behav Immun Health. 26:100563. PubMed
  60. Mittal P, et al. 2020. Cancers (Basel). :12. PubMed
  61. Gross C, et al. 2016. Neurol Neuroimmunol Neuroinflamm. 3: e289. PubMed
  62. Orlov M, et al. 2017. PLoS One.. 10.1371/journal.pone.018296. PubMed
  63. Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  64. Vacaflores A, et al. 2016. PLoS One. 11: 0157175. PubMed
  65. Johnson AM, et al. 2020. J Immunol. 204:2295. PubMed
  66. Sendler M, et al. 2020. Gastroenterology. 158:253. PubMed
  67. Huang RS, et al. 2021. Curr Protoc. 1:e246. PubMed
  68. Nice T, et al. 2016. PLoS One. 12: 1005684. PubMed
  69. Krishnan A, et al. 2020. Am J Pathol. 190:1284. PubMed
  70. Ngwenyama N, et al. 2019. JCI Insight. 4:e125527. PubMed
  71. Chen YF, et al. 2019. J Biomed Sci. 26:85. PubMed
  72. Loeuillard E, et al. 2020. J Clin Invest. 130:5380. PubMed
  73. Liu X, et al. 2009. J Immunol. 183:51:00. PubMed
  74. Gladow N, et al. 2020. PLoS One. 15:e0227734. PubMed
  75. de Picciotto S, et al. 2022. Nat Commun. 13:3866. PubMed
  76. Shafer S, et al. 2021. J Allergy Clin Immunol. 148:256. PubMed
  77. Teh MR, et al. 2021. Front Immunol. 12:714613. PubMed
  78. Ren Y, et al. 2015. Biochim Biophys Acta. Available online 14 August 2015. PubMed
  79. Mandour MF, et al. 2020. Infect Agent Cancer. 15:30. PubMed
  80. Wood M, et al. 2011. Infect Immun. 79:708. PubMed
  81. Dimeloe S, et al. 2016. J Immunol. 196: 106 - 114. PubMed
  82. Bunse C, et al. 2013. PLoS One. 8:77925. PubMed
  83. Sabag B, et al. 2022. Cancers (Basel). 14:. PubMed
  84. FitzPatrick MEB, et al. 2021. Cell Rep. 34:108661. PubMed
  85. Landi A, et al. 2017. Vaccine.. 10.1016/j.vaccine.2017.10.072. PubMed
  86. Liu X, et al. 2020. Ther Adv Med Oncol. 12:1758835920910347. PubMed
  87. Burger ML, et al. 2021. Cell. 184:4996. PubMed
  88. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  89. Mackroth M, et al. 2016. PLoS Pathog. 12:e1005909. PubMed
  90. Seenappa LM, et al. 2022. NPJ Vaccines. 7:128. PubMed
  91. Krishna B, et al. 2016. Sci Rep. 6: 24674. PubMed
  92. Schridde A, et al. 2017. Mucosal Immunol. 10.1038/mi.2016.142. PubMed
  93. Ruland C, et al. 2017. Brain Behav Immun. 10.1016/j.bbi.2017.06.010. PubMed
  94. Mattarollo S, et al. 2010. J Immunol. 184:5663. PubMed
  95. Spiljar M, et al. 2021. Cell Metab. 33:2231. PubMed
  96. Laczkó D, et al. 2020. Immunity. 53:724. PubMed
  97. Marvin S, et al. 2017. J Virol. 10.1128/JVI.01417-16. PubMed
  98. Kumar S, et al. 2021. JCI Insight. 6:e145228. PubMed
  99. Fujiwara Y, et al. 2021. Nat Commun. 12:5857. PubMed

Antigen Details

Antigen References

1. Current Protocols in Immunology (John Wiley & Sons New York) Unit 6.24 Detection of Intracellular Cytokines by Flow Cytometry (Barbara Foster and Calman Prussin NIAID NIH Bethesda MD).
2. Sander B, et al. 1991. Immunol. Rev. 119:65.
3. Sander B, et al. 1993. J. Immunol. Meth. 166:201.
4. Prussin C, et al. 1995. J. Immunol. Meth. 188:117.
5. Jung T, et al. 1993. J. Immunol. Meth. 159:197.

Gene ID
NA

Related FAQs

How do I choose monensin or Brefeldin A solution?

Generally, Brefeldin A is more toxic for longer term incubations, so for shorter stimulations (6 hrs or less) use Brefeldin A.  For longer stimulations use monensin.  We recommend optimization for each cell type and protocol.

Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account